News
May 5, 2023
Amador Bioscience Welcomes Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology
Pleasanton, Calif., May 5, 2023: Amador Bioscience, a full-service CRO with global expertise in translational research and clinical ...
Mar 7, 2023
Dr. Lorin K. Roskos, Biopharmaceutical Leader and Executive, Joins Amador Bioscience’s Board of Directors
Amador Bioscience, a full-service CRO with global expertise in translational research and clinical development, announces the appointment ...
Nov 2, 2022
Amador Bioscience Opens New State-of-the-Art GxP Facility in Maryland
Germantown, Md.: Amador Bioscience, a global translational and clinical research CRO, is pleased to announce the grand opening of its GxP ...
Oct 28, 2022
Amador Bioscience and BIOMED Finalize Collaboration
Pleasanton, Calif.: Amador Bioscience, a clinical CRO with world-class clinical pharmacology and pharmacometrics expertise, today announced ...
Oct 21, 2022
Amador Bioscience Appoints Dr. Howard Yuwen as Senior Vice President of Global Regulatory Affairs
Pleasanton, Calif.: Amador Bioscience, a full-service CRO with global expertise in translational research and clinical development, ...
Sep 21, 2022
More Than Four Million Euros for Third-phase Expansion of Netherland-based BioVille
Thursday, September 8, 2022 at 3:25 a.m.
Sep 12, 2022
Amador Bioscience and Ann Arbor Pharmacometrics Group Further Align to Take End-to-End Drug Development Into the Future
In December of 2021, Ann Arbor Pharmacometrics Group (A2PG) joined forces with Amador Bioscience to strengthen its global leadership in ...
Mar 10, 2022
Amador Bioscience Establishes Clinical Division in Hangzhou
On March 10, 2022, Amador Bioscience announced the establishment of a new clinical business unit in Hangzhou. Patrick Hu, MD, was appointed ...
Jan 10, 2022
Dr. Meina Liang Joins Amador Bioscience as Chief Technology Officer
On January 10, 2022, Amador Bioscience announced the appointment of Dr. Meina Liang, PhD, a world-renowned innovative drug R&D and ...
Dec 31, 2021
Translational Science and Clinical Pharmacology CRO, Amador Bioscience, Announces the Completion of Over $60 Million in Series B+ Financing
The new round of financing was led by Heyu Capital (MSA), and the existing shareholders Sequoia China, Hillhouse Ventures, and Kaifeng ...
Dec 24, 2021
Amador Bioscience Acquires Ann Arbor Pharmacometrics Group (A2PG)
Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that it has completed the acquisition of ...
Nov 28, 2021
Amador Bioscience Expands to Belgium
The Biopharmaceutical Ecosystem Development Seminar jointly organized by the Provincial Government of Limburg, Belgium, Amador Bioscience ...
Nov 4, 2021
Strategic Cooperation Agreement Between Amador Bioscience and Belgian Government
Recently, Amador Biotech signed a strategic cooperation with the Belgian government. Tom Vandeput, Deputy Governor of Limburg Province in ...
